Across TCGA pan-cancer cohorts, NBPF22P Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NBPF22P data layer compared with 16 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher NBPF22P Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated NBPF22P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, PAAD, and CESC are the cancer types where NBPF22P Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.